Development of New Hepatitis E Vaccines

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2018 May 1

PMID 29708836

Citations 12

Authors

Yufeng Cao

Zhenhong Bing

Shiyu Guan

Zecai Zhang

Xinping Wang

Affiliations

Soon will be listed here.

Abstract

Hepatitis E virus (HEV) infection is an emerging zoonotic disease posing a severe threat to public health in the world, especially to pregnant women. Currently, no specific treatments are available for HEV infection. Therefore, it is crucial to develop vaccine to prevent this infection. Although several potential candidate vaccines against HEV have been studied for their immunogenicity and efficacy, only Hecolin® which is developed by Xiamen Innovax Biotech Co., Ltd. and approved by China Food and Drug Administration (CFDA) in 2012, is the licensed HEV vaccine in the world so far. Extensive studies on safety, immunogenicity and efficacy in phase III clinical trials have shown that Hecolin® is a promising vaccine for HEV prevention and control. In this article, the advances on HEV vaccine development and research are briefly reviewed.

Citing Articles

Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections.

Ren M, Abdullah S, Pei C, Guo H, Sun S Vet Res. 2024; 55(1):128.

PMID: 39350170 PMC: 11443892. DOI: 10.1186/s13567-024-01383-x.

Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved SliC antigen that blocks human lysozyme.

Martinez F, Zielke R, Fougeroux C, Li L, Sander A, Sikora A Infect Immun. 2023; 91(12):e0024523.

PMID: 37916806 PMC: 10715030. DOI: 10.1128/iai.00245-23.

Viral Replicon Systems and Their Biosafety Aspects.

van der Meulen K, Smets G, Rudelsheim P Appl Biosaf. 2023; 28(2):102-122.

PMID: 37342518 PMC: 10278005. DOI: 10.1089/apb.2022.0037.

Porcine Deltacoronavirus-like Particles Produced by a Single Recombinant Baculovirus Elicit Virus-Specific Immune Responses in Mice.

Liu Y, Han X, Qiao Y, Wang T, Yao L Viruses. 2023; 15(5).

PMID: 37243181 PMC: 10221120. DOI: 10.3390/v15051095.

Virus-like particle vaccinology, from bench to bedside.

Mohsen M, Bachmann M Cell Mol Immunol. 2022; 19(9):993-1011.

PMID: 35962190 PMC: 9371956. DOI: 10.1038/s41423-022-00897-8.

References

Li H, Gang H, Sun Q, Liu X, Ma Y, Sun M . Production in Pichia pastoris and characterization of genetic engineered chimeric HBV/HEV virus-like particles. Chin Med Sci J. 2004; 19(2):78-83. View

Zhang J, Shih J, Wu T, Li S, Xia N . Development of the hepatitis E vaccine: from bench to field. Semin Liver Dis. 2013; 33(1):79-88. DOI: 10.1055/s-0033-1338116. View

Xiang K, Kusov Y, Ying G, Yan W, Shan Y, Jinyuan W . A Recombinant HAV Expressing a Neutralization Epitope of HEV Induces Immune Response against HAV and HEV in Mice. Viruses. 2017; 9(9). PMC: 5618026. DOI: 10.3390/v9090260. View

Beran J, Van Der Meeren O, Leyssen M, Dsilva P . Immunity to hepatitis A and B persists for at least 15 years after immunisation of adolescents with a combined hepatitis A and B vaccine. Vaccine. 2016; 34(24):2686-91. DOI: 10.1016/j.vaccine.2016.04.033. View

Behloul N, Wei W, Baha S, Liu Z, Wen J, Meng J . Effects of mRNA secondary structure on the expression of HEV ORF2 proteins in Escherichia coli. Microb Cell Fact. 2017; 16(1):200. PMC: 5686824. DOI: 10.1186/s12934-017-0812-8. View

Cao Y, Tao H, Hu Y, Shi C, Wu X, Liang Q . A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine. Vaccine. 2017; 35(37):5073-5080. DOI: 10.1016/j.vaccine.2017.05.072. View

Wang H, Zhang W, Gu H, Chen W, Zeng M, Ji C . Identification and characterization of two linear epitope motifs in hepatitis E virus ORF2 protein. PLoS One. 2017; 12(9):e0184947. PMC: 5619941. DOI: 10.1371/journal.pone.0184947. View

Geng Y, Zhao C, Fan J, Harrison T, Zhang H, Lian H . Genotype analysis of hepatitis E virus from sporadic hepatitis E cases in northern China. Infect Genet Evol. 2013; 20:413-7. DOI: 10.1016/j.meegid.2013.10.003. View

Tong Y, Zhan M, Lu J, Bai Y, Bi S . [Immunogenicity of recombinant HEV ORF2 protein expressed in pichia pastoris]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2002; 16(1):23-6. View

10.

Wu X, Chen P, Lin H, Hao X, Liang Z . Hepatitis E virus: Current epidemiology and vaccine. Hum Vaccin Immunother. 2016; 12(10):2603-2610. PMC: 5085000. DOI: 10.1080/21645515.2016.1184806. View

11.

Nakano T, Takahashi K, Takahashi M, Nishigaki Y, Watanabe N, Ishida S . Investigating the origin and global dispersal history of hepatitis E virus genotype 4 using phylogeographical analysis. Liver Int. 2015; 36(1):31-41. DOI: 10.1111/liv.12880. View

12.

Su C, Gu M, Zhang P, Jin Z, Meng F, Chen E . [Expression of ORF2 protein of HEV genotype IV in Hansenula polymorpha]. Sheng Wu Gong Cheng Xue Bao. 2007; 23(1):73-8. View

13.

Shrestha M, Scott R, Joshi D, Mammen Jr M, Thapa G, Thapa N . Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med. 2007; 356(9):895-903. DOI: 10.1056/NEJMoa061847. View

14.

Chandra V, Taneja S, Kalia M, Jameel S . Molecular biology and pathogenesis of hepatitis E virus. J Biosci. 2009; 33(4):451-64. DOI: 10.1007/s12038-008-0064-1. View

15.

Aggarwal R, Shukla R, Jameel S, Agrawal S, Puri P, Gupta V . T-cell epitope mapping of ORF2 and ORF3 proteins of human hepatitis E virus. J Viral Hepat. 2007; 14(4):283-92. PMC: 2441432. DOI: 10.1111/j.1365-2893.2006.00796.x. View

16.

Wedemeyer H, Pischke S, Manns M . Pathogenesis and treatment of hepatitis e virus infection. Gastroenterology. 2012; 142(6):1388-1397.e1. DOI: 10.1053/j.gastro.2012.02.014. View

17.

Wen J, Behloul N, Dai X, Dong C, Liang J, Zhang M . Immunogenicity difference between two hepatitis E vaccines derived from genotype 1 and 4. Antiviral Res. 2016; 128:36-42. DOI: 10.1016/j.antiviral.2016.02.002. View

18.

Kwo P, Schlauder G, CARPENTER H, Murphy P, Rosenblatt J, Dawson G . Acute hepatitis E by a new isolate acquired in the United States. Mayo Clin Proc. 1997; 72(12):1133-6. DOI: 10.4065/72.12.1133. View

19.

Wong D, Purcell R, Sreenivasan M, Prasad S, Pavri K . Epidemic and endemic hepatitis in India: evidence for a non-A, non-B hepatitis virus aetiology. Lancet. 1980; 2(8200):876-9. DOI: 10.1016/s0140-6736(80)92045-0. View

20.

Purdy M, McCaustland K, Krawczynski K, Spelbring J, Reyes G, Bradley D . Preliminary evidence that a trpE-HEV fusion protein protects cynomolgus macaques against challenge with wild-type hepatitis E virus (HEV). J Med Virol. 1993; 41(1):90-4. DOI: 10.1002/jmv.1890410118. View